Treatment with Tafamidis in patients with transthyretin amyloid cardiomyopathy

被引：0
|
作者：
Rettl, R. [1 ]
Christopher, M. [1 ]
Dachs, T. [1 ]
Duca, F. [1 ]
Binder, C. [1 ]
Dusik, F. [1 ]
Seirer, B. [1 ]
Eslam, R. Badr [1 ]
Hengstenberg, C. [1 ]
Bonderman, D. [1 ]
机构：
[1] Med Univ Wien, Vienna, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2020年 / 132卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PS 26/26-6
引用
收藏
页码：S306 / S307
页数：2
相关论文
共 50 条
  • [21] Tafamidis Should Be Accessible for All Patients With Transthyretin Amyloid Cardiomyopathy
    Psotka, Mitchell A.
    JACC-HEART FAILURE, 2021, 9 (02) : 124 - 126
  • [22] Mortality Among Older Transthyretin Amyloid Cardiomyopathy Patients On Tafamidis
    Batra, Supria
    Patel, Hina
    Govi, Ashley
    Panjrath, Gurusher
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
  • [23] Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05): : 505 - 505
  • [24] Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
    Wang, Jie
    Chen, Hongyu
    Tang, Zihuan
    Zhang, Jinquan
    Xu, Yuanwei
    Wan, Ke
    Hussain, Kifah
    Gkoutos, Georgios, V
    Han, Yuchi
    Chen, Yucheng
    ECLINICALMEDICINE, 2023, 63
  • [25] Tafamidis (Vyndagel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1590): : 16 - 16
  • [26] Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy
    Rettl, R.
    Wollenweber, T.
    Mann, C.
    Duca, F.
    Dachs, T.
    Binder, C.
    Stojanovic, M.
    Ligios, L. Camuz
    Schrutka, L.
    Dalos, D.
    Charwat-Resl, S.
    Hengstenberg, C.
    Eslam, R. Badr
    Kastner, J.
    Hacker, M.
    Bonderman, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (SUPPL 3) : S105 - S106
  • [27] Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy
    Badr Eslam, Roza
    Ozturk, Begum
    Rettl, Rene
    Capelle, Christophe Denis Josef
    Qin, Hong
    Binder, Christina
    Dachs, Theresa-Marie
    Camuz Ligios, Luciana
    Duca, Franz
    Dalos, Daniel
    Schrutka, Lore
    Alasti, Farideh
    Kastner, Johannes
    Vila, Greisa
    Bonderman, Diana
    CIRCULATION-HEART FAILURE, 2022, 15 (07)
  • [28] Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy
    Rettl, R. Rene
    Wollenweber, T.
    Mann, C.
    Duca, F.
    Dachs, T-M
    Binder, C.
    Stojanovic, M.
    Ligios, L. Camuz
    Schrutka, L.
    Dalos, D.
    Charwat-Resl, S.
    Eslam, R. Badr
    Kastner, J.
    Hacker, M.
    Bonderman, D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 253 - 253
  • [29] Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
    Rettl, Rene
    Wollenweber, Tim
    Duca, Franz
    Binder, Christina
    Cherouny, Bernhard
    Dachs, Theresa-Marie
    Ligios, Luciana Camuz
    Schrutka, Lore
    Dalos, Daniel
    Beitzke, Dietrich
    Loewe, Christian
    Eslam, Roza Badr
    Kastner, Johannes
    Hacker, Marcus
    Bonderman, Diana
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2023, 24 (08) : 1019 - 1030
  • [30] Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)
    Hanna, Mazen
    Damy, Thibaud
    Grogan, Martha
    Stewart, Michelle
    Gundapaneni, Balarama
    Patterson, Terrell A.
    Schwartz, Jeffrey H.
    Sultan, Marla B.
    Maurer, Mathew S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 141 : 98 - 105
12345